Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Maribavir

- PMLiVE

The Power of Disease Awareness in Infectious Disease Education at IDWeek 2023

Medscape Education had one of its biggest conferences of the year with IDWeek 2023, hosting six educational symposia and presenting five scientific posters highlighting the outcomes of recent infectious disease...

Medscape Education Global

- PMLiVE

The Lasting Impact of Cytomegalovirus Education 

Education on the signs, symptoms, and potential complications of cytomegalovirus (CMV) is in need of constant development, as this common disease affects nearly 1 in 3 children by age 5...

Medscape Education Global

Medscape Education: ACOG 2023 Publication

Medscape Education is making a difference! We are wrapping CMV Awareness Month with a look at the impact of CMV education on OB/GYN learners. Take a look as Medscape Senior...

Medscape Education Global

- PMLiVE

Takeda to sell Japan consumer health unit for $2.3bn

Deal helps to reduce debt accrued from Shire takeover

- PMLiVE

Mergers and acquisitions: agents for change

Getting the best from your agency in a disruptive time

Bedrock Healthcare Communications

- PMLiVE

Takeda’s subcutaneous Entyvio formulation faces FDA rejection

Was seeking approval in moderate-to-severe ulcerative colitis

- PMLiVE

Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day

First wave of new molecular entities has potential to generate 14 approvals

- PMLiVE

Takeda divests over-the-counter and prescription drugs to Stada for $660m

Japanese pharma said it has plans to divest $10bn in non-core assests

- PMLiVE

Takeda offloads select portfolio to Acino ahead of Shire takeover

Hopes to reduce debt before acquistion completion

- PMLiVE

Shire bags US approval for constipation drug Motegrity

Approval is boost as Takeda takeover nears completion

- PMLiVE

Takeda secures investor backing for £46bn Shire takeover

The deal is expected to close early next year

- PMLiVE

Shire’s angioedema drug Takhzyro claims EU approval

Approval shortly follows a green light in the US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links